Role of antiviral therapy in respiratory infections in children: analysis of clinical and laboratory observations
Authors:   N.I.Pirogov Russian National Research Medical University, Moscow, Russian Federation, Savenkova M.S. , Isaeva E.I. ,   N.F.Gamaleya National Research Centre of Epidemiology and Microbiology, Moscow, Russian Federation, Vetrova E.N. ,   N.F.Gamaleya National Research Centre of Epidemiology and Microbiology, Moscow, Russian Federation, Kraseva G.N. ,   Polyclinic No 2, Clinical and Diagnostic Center of Gazprom, Moscow, Russian Federation, Abramova N.A. ,   Polyclinic No 2, Clinical and Diagnostic Center of Gazprom, Moscow, Russian Federation, Shabat M.B. ,   Polyclinic No 2, Clinical and Diagnostic Center of Gazprom, Moscow, Russian Federation, Dushkin R.V. ,   Artificial Intelligence Agency LLC, Moscow, Russian Federation, Fadeeva S. ,   Artificial Intelligence Agency LLC, Moscow, Russian Federation, Kontio S.V. ,   Artificial Intelligence Agency LLC, Moscow, Russian Federation, Savenkov M.P. ,   N.I.Pirogov Russian National Research Medical University, Moscow, Russian Federation
Published: March 2023

Objective. To evaluate the efficacy of therapy for acute respiratory viral infections (ARVIs) in children with antiviral medications: inosine pranobex (Groprinosin®, Gedeon Richter) and Kagocel (Kagocel®, Niarmedic Pharma LLC) in comparison with symptomatic treatment without etiotropic agents based on clinical and laboratory parameters. Patients and methods. The clinical and laboratory observation was conducted in an outpatient setting in the pre-COVID-19 period between 2018 and 2020. Acute respiratory infections were diagnosed using licensed testing systems by multiplex polymerase chain reaction (PCR) with detection of nucleic acid viral genomes: influenza, rhinovirus, respiratory syncytial virus, metapneumovirus, parainfluenza, seasonal coronaviruses, adenoviruses, and bocavirus). A total of 151 children aged 3 to 15 years were examined and monitored in dynamics, with 78.7% of positive and 21.3% of negative results detected by PCR in the nasopharyngeal and oropharyngeal swabs. The patients were randomized into three groups depending on the antiviral medication prescribed: group 1 (53 children) received Groprinosin®; group 2 (52 children) received Kagocel®; group 3 (control, 46 children) received only symptomatic therapy without antiviral agents. Results. The study demonstrated a significant positive effect in patients in group 1 treated with Groprinosin® (n = 53). At the end of therapy for both mono- and mixed infections, there were 95.8% of negative results (according to PCR diagnosis, that is, the absence of viral genome). In children in group 2 (n = 52) treated with Kagocel®, the absence of viral nucleic acids (NAs) was observed less frequently (in 77.3% of cases). In children in group 3 (n = 46) who did not receive etiotropic antiviral therapy, there were only 40.3% of negative results after the end of treatment, and viral NAs were detected in 59.7% of patients. In this case, a 5-day course of Groprinosin® was prescribed, after which the PCR results became negative in all patients. Therefore, children with recurrent respiratory infections, mixed infections, and herpesvirus infections require longer therapy. Additionally, a high frequency of ARVI complications was noted in group 3 (5 (10.9%) patients, where otitis was observed in 1 case, sinusitis – in 2 cases, bronchitis – in 2 cases), whereas 1 (1.8%) patient taking Groprinosin® had otitis, and 1 (1.9%) patient taking Kagocel® had pneumonia. Conclusion. This study was the first to investigate antibody titers to respiratory viruses in dynamics at 3, 6 and 12 months after the onset of ARVI. It showed that the development of antibodies to respiratory viruses is very unstable and does not occur in all patients. Antibodies almost disappeared by the third month after ARVI and were no longer detectable by the sixth month. After 12 months, patients suffered a new ARVI and developed the corresponding antibodies. This information will be especially relevant in conditions of the rise in the incidence of ARVIs, as well as the COVID-19 pandemic observed in recent years. Key words: antiviral agents, polymerase chain reaction, specific antibodies to acute respiratory viral infections, children, clinical and laboratory dynamics, inosine pranobex, Groprinosin®, Kagocel®